GRAIL, Inc. (GRAL) Financial Analysis & Valuation | Quarter Chart
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom ... more
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $5.92B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Joshua J. Ofman |
| IPO Date | 2024-06-12 | CAGR | — |
| Employees | 910 | Website | grail.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GRAL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $6.18B | P/E | -13.6 | Forward P/E | -16.07 | PEG | — |
| P/S | 73600808216.42 | P/B | 4773447294.87 | P/CF | -32021431097.08 | P/FCF | -31773391400.28 |
| Sales | $165.26M | Sales 1Y | 23.07% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-9.75 | EPS 1Y | -25.63% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 9.57% | EPS QoQ | 11.79% | Sales QoQ Avg | 6.35% | EPS QoQ Avg | -4.45% |
| Gross Margin | -10.83% | Operating Margin | -338.4% | Profit Margin | -236.95% | ROCE | -20.26% |
| ROA | -14% | ROE | -16% | Altman Z Score | 6.47 | Piotroski Score | 4 |
| Current Ratio | 10.95 | Quick Ratio | 10.74 | Cash Ratio | 0.67 | Op. CF Ratio | -2.01 |
| Debt/Equity | 0.04 | Debt/Assets | 0.03 | Lt Debt/Equity | 0.03 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | 10.31 | Asset Turnover | 0.06 | Receivables Turnover | 8.36 |
| Enterprise Value | $6.18B | P/E Ratio | -13.6 |
| Forward P/E | -16.07 | PEG Ratio | — |
| P/S Ratio | 73600808216.42 | P/B Ratio | 4773447294.87 |
| P/CF Ratio | -32021431097.08 | P/FCF Ratio | -31773391400.28 |
| EPS | $-9.75 | EPS Growth 1Y | -25.63% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 23.07% | Gross Margin | -10.83% |
| Operating Margin | -338.4% | Profit Margin | -236.95% |
| ROE | -16% | ROA | -14% |
| ROCE | -20.26% | Current Ratio | 10.95 |
| Quick Ratio | 10.74 | Cash Ratio | 0.67 |
| Debt/Equity | 0.04 | Interest Coverage | — |
| Altman Z Score | 6.47 | Piotroski Score | 4 |
GRAIL, Inc. (GRAL) valuation & financials
GRAIL, Inc. (GRAL) has a market capitalization of $5.92B and trades at a price-to-earnings ratio of -13.6. It operates in the Healthcare sector (Medical - Diagnostics & Research).
GRAIL, Inc.'s revenue grew +23.1% over the last year.
GRAIL, Inc.'s next earnings report is scheduled for November 11, 2026 (provider scheduled date); analysts estimate EPS of $-2.50. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)